Medtech, Biotechnology Veteran Joins InVivo Therapeutics’ Board of Directors

InVivo Therapeutics Holdings Corp. has appointed Robert J. Rosenthal, Ph.D., to its Board of Directors. Dr. Rosenthal brings more than 25 years of experience to the InVivo Board as an accomplished executive and business leader in the biotechnology, therapeutics, and medical device industries. With the addition of Dr. Rosenthal, InVivo’s Board has six members, five of whom are independent.
 
“Dr. Rosenthal’s deep experience across a range of corporate functions, from corporate development and business operations, to strategic planning and capital market transactions, will be a highly valuable addition to our Board as we guide the company forward toward its near- and long-term goals,” said Ann Merrifield, InVivo’s board chair.
 
Dr. Rosenthal currently serves as chairman of the Board of Taconic Biosciences Inc., a privately-held provider of research models for the pharmaceutical and biotech industry, where from 2014 to 2018 he also served as CEO. Dr. Rosenthal also currently serves as a director of the Bruker Corporation, a publicly traded manufacturer of analytic instruments, since 2015. Dr. Rosenthal has served since 2007 as a director of Safeguard Scientifics Inc., a publicly-traded provider of capital for early- and growth-stage companies, and as chairman of its board of directors since May 2016. He also currently serves as a director of Galvanic Applied Sciences Inc., a privately-held Canadian company, since 2013.
 
“I am excited to join the InVivo Board at this critical period in the company’s history, and I look forward to working together with the board and the InVivo team as InVivo continues advancing down its clinical pathway to ultimately address an area of significant unmet need for spinal cord injury patients,” commented Dr. Rosenthal.
 
Dr. Rosenthal has more than 25 years of experience in a variety of senior management positions with companies involved in the development of therapeutics, medical devices, diagnostics, and life sciences tools, most recently including from 2010 through 2012 as president and CEO of IMI Intelligent Medical Implants AG, a medical technology company, and from 2005 through 2009 as president and CEO of Magellan Biosciences Inc., a provider of clinical diagnostics and life sciences research tools. Earlier in his career, Dr. Rosenthal served in senior management positions at Perkin Elmer Inc. and Thermo Fisher Scientific Inc.
 
Dr. Rosenthal earned his Ph.D. from Emory University and a master’s degree of science from the State University of New York.

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital.